Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: A Post-ASH 2009 discussion

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 4, 2010, Pages 1-12

  Czuczman, Myron S ^a   Leonard, John P ^b   Williams, Michael E ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; IMMUNOMODULATING AGENT; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN KINASE B; RITUXIMAB; SALINOSPORAMIDE A; TEMSIROLIMUS; THALIDOMIDE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, MANTLE-CELL; NITROGEN MUSTARD COMPOUNDS; PREDNISONE; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; VINCRISTINE;

EID: 79951492214     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Montagut C, Rovira A, Albanell J. The proteasome: a novel target for anticancer therapy. Clin Transl Oncol. 2006;8:313-317.
2. Moran E, Nencioni A. The role of proteasome in malignant diseases. J BUON. 2007;(12 suppl 1):S95-S99.
3. Testa U. Proteasome inhibitors in cancer therapy. Curr Drug Targets. 2009;10: 968-981.
4. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11:164-179.
5. Velcade [package insert]. Cambridge, MA: Millennium Pharmaceuticals Inc; 2009.
6. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867-4874.
7. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13:5291-5294.
8. Ruan J, Martin P, Furman RR, et al. CHOP-R + bortezomib as initial therapy for mantle cell lymphoma (MCL). Blood. 2009;114. Abstract 2682.
9. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15:3081-3094.
10. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20:1288-1294.
11. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
12. Friedberg JW, Vose JM, Kelly JL, et al. Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter phase II clinical trial. Blood. 2009;114. Abstract 924.
13. Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the phase 2 VERTICAL study. Blood. 2009;114. Abstract 933.
14. Yang H, Zonder JA, Dou QP. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs. 2009;18:957-971.
15. O'Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15: 7085-7091.
16. Vij R, Wang L, Orlowski RZ, et al. Carfilzomib (CFZ), a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects. Blood. 2009;114. Abstract 430.
17. Badros AZ, Vij R, Martin T, et al. Phase I study of carfilzomib in patients (pts) with relapsed and refractory multiple myeloma (MM) and varying degrees of renal insufficiency. Blood. 2009;114. Abstract 3877.
18. Niesvizky R, Wang L, Orlowski RZ, et al. Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). Blood. 2009;114. Abstract 304.
19. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009;23:1964-1979.
20. Richardson P, Hofmeister C, Jakubowiak A, et al. Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (MM). Blood. 2009;114. Abstract 431.
21. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 2009;(36 suppl 3):S3-S17.
22. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma. 2009;50:1916-1930.
23. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113:508-514.
24. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347-5356.
25. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822-3829.
26. Ansell SM, Tang H, Kurtin P, et al. A phase II study of temsirolimus (CCI-779) in combination with rituximab in patients with relapsed or refractory mantle cell lymphoma. Blood. 2009;114. Abstract 1665.
27. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12:5165-5173.
28. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia. 2007;21:333-339.
29. Ogura M, Uchida T, Maruyama D, et al. Phase I and pharmacokinetic (PK) study of everolimus (RAD001) in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Blood. 2009;114. Abstract 1712.
30. Gandhi V, Burger JA. Bendamustine in B-cell malignancies: the new 46-year-old kid on the block. Clin Cancer Res. 2009;15:7456-7461.
31. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309-317.
32. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27:1492-501.
33. Treanda [package insert]. Frazer, PA: Cephalon Inc; 2010.
34. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378-4384.
35. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010:116:106-114.
36. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-4479.
37. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
38. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114. Abstract 405.
39. ClinicalTrials.gov. Study of bendamustine hydrochloride in combination with rituximab in the treatment of patients with relapsed/refractory mantle cell lymphoma. Identifier: NCT00891839. Available at: http://clinicaltrials.gov/ct2/show/NCT00891839?term=NCT00891839&rank=1. Accessed April 14, 2010.
40. Moosmann P, Heizmann M, Kotrubczik N, Wernli M, Bargetzi M. Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51:149-152.
41. Friedberg JW, Vose JM, Kelly JL, et al. Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter phase II clinical trial. Blood. 2009;114. Abstract 924.
42. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol. 2006;132:105-112.
43. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009; 114:3367-3375.
44. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol. 2005; 32:S24-3S0.
45. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114: 4713-4720.
46. Revlimid [package insert]. Summit, NJ: Celgene Corporation; 2009.
47. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343-5349.
48. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291-5297.
49. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26:2519-2525.
50. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952-4957.
51. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:5404-5409.
52. Witzig TE, Vose JM, Zinzani PL, et al. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013- NHL-003). Blood. 2009;114. Abstract 1676.
53. Vose JM, Habermann T, Czuczman MS, et al. Single-agent lenalidomide for patients with relapsed/refractory aggressive non-Hodgkin's lymphoma who had received prior stem cell transplant. Blood. 2009;114. Abstract 2699.
54. Wang L, Fayad L, Hagemeister FB, et al. A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma. Blood. 2009;114. Abstract 2719.
55. Zhao JJ, Lin J, Lwin T, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010;115:2630-2639.
56. Budde LE, Zhang MM, Shustov AR, et al. A phase I study of vorinostat (V) in combination with rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) for patients with relapsed or refractory lymphoid malignancies or untreated T- or mantle cell lymphoma. Blood. 2009;114. Abstract 3696.
57. Watanabe T, Kato H, Kobayashi Y, et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci. 2010;101:196-200.
58. Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma. 2009;50:728-735.
59. ClinicalTrials.gov. Bevacizumab + CHOP-rituximab in untreated mantle cell lymphoma. Identifier: NCT00401817. Available at: http://clinicaltrials.gov/ct2/show/NCT00401817?term=NCT00401817&rank=1. Accessed April 7, 2010.
60. Kolstad A, Laurell A, Andersen NS, et al. 90y-Ibritumumab tiuxetan (Zevalin®)- BEAM/C with autologous stem cell support as frontline therapy for advanced mantle cell lymphoma. Preliminary results from the third Nordic MCL phase II study (MCL3) Blood. 2009;114. Abstract 932.
61. Kirschbaum M, Delioukina M, Popplewell L, et al. Phase I study of bortezomib in combination with gemcitabine in relapsed/refractory intermediate grade B-cell and mantle cell non-Hodgkin's lymphoma. Blood. 2009;114. Abstract 1682.
62. Witzig TE, Vose JM, Zinzani PL, et al. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013- NHL-003). Blood. 2009;114. Abstract 1676.
63. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114. Abstract 405.
64. Zhao JJ, Lin J, Lwin T, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010;115:2630-2639.
65. Budde LE, Zhang MM, Shustov AR, et al. A phase I study of vorinostat (V) in combination with rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) for patients with relapsed or refractory lymphoid malignancies or untreated T- or mantle cell lymphoma. Blood. 2009;114. Abstract 3696.
66. Watanabe T, Kato H, Kobayashi Y, et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci. 2010;101:196-200.
67. Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma. 2009;50:728-735.
68. ClinicalTrials.gov. Bevacizumab + CHOP-rituximab in untreated mantle cell lymphoma. Identifier: NCT00401817. Available at: http://clinicaltrials.gov/ct2/show/NCT00401817?term=NCT00401817&rank=1. Accessed April 7, 2010.
69. Kolstad A, Laurell A, Andersen NS, et al. 90y-Ibritumumab tiuxetan (Zevalin®)- BEAM/C with autologous stem cell support as frontline therapy for advanced mantle cell lymphoma. Preliminary results from the third Nordic MCL phase II study (MCL3) Blood. 2009;114. Abstract 932.
70. Kirschbaum M, Delioukina M, Popplewell L, et al. Phase I study of bortezomib in combination with gemcitabine in relapsed/refractory intermediate grade B-cell and mantle cell non-Hodgkin's lymphoma. Blood. 2009;114. Abstract 1682.
71. Witzig TE, Vose JM, Zinzani PL, et al. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013- NHL-003). Blood. 2009;114. Abstract 1676.
72. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114. Abstract 405.